Amgen vs. Vertex Pharmaceuticals: A Comparison of Revenue Scale and Growth Trajectories
This analysis compares the financial performance and market positioning of Amgen (AMGN) and Vertex Pharmaceuticals (VRTX). Amgen operates at a significantly larger scale, with quarterly revenues projected to reach over $10 billion by mid-2026, driven primarily by its oncology and cardiovascular portfolios. While Amgen shows moderate quarter-over-quarter fluctuations due to healthcare seasonality, it maintains a massive revenue base. Vertex Pharmaceuticals demonstrates steadier, more gradual growth focused on cystic fibrosis treatments and expanding therapeutic areas. The company is diversifying through the development of Povetacicept for autoimmune diseases and the global rollout of its once-daily CF regimen, Alyftrek. Vertex's expansion into new indications like IgA nephropathy could potentially unlock multi-billion dollar peak annual sales, offering a different growth profile compared to Amgen's large-scale stability.
Topics: biotechnology FDA approval M&A revenue growth